

Chapter 157

Scleroderma

P. Moinzadeh, Christopher P. Denton,
T. Krieg, & Carol M. Black

REFERENCES

1. Mayes M et al: Prevalence, Incidence, Survival, and Disease Characteristics of Systemic Sclerosis in a Large US Population. *Arthritis Rheum* 48:2246-2255, 2003
2. Silman AJ: Epidemiology of scleroderma. *Curr Opin Rheumatol* 3:967-972, 1991
3. Tamaki T et al: Epidemiological study of patients with systemic sclerosis in Tokyo. *Arch Dermatol Res* 283:366-371, 1991
4. Hunzelmann N et al: The registry of the German Network for Systemic Scleroderma: Frequency of disease subsets and patterns of organ involvement. *Rheumatology (Oxford)* 47:1185-1192, 2008
5. Medsger TA Jr, Masi AT: Epidemiology of systemic sclerosis (scleroderma). *Ann Intern Med* 74:714-721, 1971
6. Agarwal S et al: Genetics and Genomic Studies in Scleroderma (Systemic Sclerosis). *Rheum Dis Clin N Am* 34:17-40, 2008
7. Assassi S et al: Clinical, immunologic, and genetic features of familial systemic sclerosis. *Arthritis Rheum* 56:2031-2037, 2007
8. Arnett FC et al: Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. *Arthritis Rheum* 39:1151-1160, 1996
9. Marguerie C et al: The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen Pm-Scl. *Medicine (Baltimore)* 71:327-336, 1992
10. Assassi S, Tan FK: Genetics of scleroderma: Update on single nucleotide polymorphism analysis and microarrays. *Curr Opin Rheumatol* 17:761, 2005
11. Herrick AL, Worthington J: Genetic epidemiology Systemic sclerosis. *Arthritis Res* 4:165-168, 2002
12. Ho KT, Reveille JD: The clinical relevance of autoantibodies in scleroderma. *Arthritis Res Ther* 5:80-93, 2003
13. Kraaling BM et al: Mononuclear cell infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. *Pathobiology* 63:48-56, 1995
14. Roumm AD et al: Lymphocytes in the skin of patients with progressive systemic sclerosis: Quantification, subtyping, and clinical correlations. *Arthritis Rheum* 27:645-653, 1984
15. Mavalia C et al: Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. *Am J Pathol* 151:1751-1758, 1997
16. Hasegawa M et al: Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. *J Rheumatol* 24:328-332, 1997
17. Kurasawa K et al: Increased interleukin-17 production in patients with systemic sclerosis. *Arthritis Rheum* 43:2455-2463, 2000
18. Prescott RJ et al: Sequential dermal microvascular and perivascular changes in the development of scleroderma. *J Pathol* 166:255-263, 1992
19. Sainson RC et al: TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. *Blood* 11:4997-5007, 2008
20. Brinckmann J et al: Interleukin 4 and prolonged hypoxia induce a higher gene expression of lysyl hydroxylase 2 and an altered cross-link pattern: Important pathogenetic steps in early and late stage of systemic scleroderma? *Matrix Biol* 24:459-468, 2005
21. Gabrielli A et al: Scleroderma. *N Engl J Med* 360:1989-2003, 2009
22. Kawakami T et al: Increased expression of TGF-beta receptors by scleroderma fibroblasts: Evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. *J Invest Dermatol* 110:47-51, 1998
23. Baroni SS et al: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. *N Engl J Med* 354:2667-2676, 2006
24. Abraham DJ et al: Overview of pathogenesis of systemic sclerosis. *Rheumatology (Oxford)* 48:iii3-iii7, 2009
25. Nietert PJ, Silver RM: Systemic sclerosis: Environmental and occupational risk factors. *Curr Opin Rheumatol* 12:540, 2000

26. Mayes MD: Epidemiologic studies of environmental agents and systemic autoimmune diseases. *Environ Health Perspect* **107**:743, 1999
27. Jablonska S, Blaszczczyk M: Scleroderma-like disorders. *Semin Cutan Med Surg* **17**:65, 1998
28. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary Criteria for the classification of systemic sclerosis (scleroderma). *Arthritis Rheum* **23**:581-590, 1980
29. LeRoy EC et al: Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. *J Rheumatol* **15**:202-205, 1988
30. Le Roy EC, Medsger TA Jr.: Criteria for the classification of early systemic sclerosis. *J Rheumatol* **28**:1573-1576, 2001
31. Walker JG et al: The development of systemic sclerosis classification criteria. *Clin Rheumatol* **26**:1401-1409, 2007
32. Nadashkevich O, Davis P, Fritzler MJ: Revising the classification criteria for systemic sclerosis. *Arthritis Rheum* **55**(6):992-993, 2006
33. Maricq HR, Valter I: A working classification of scleroderma spectrum disorders: A proposal and the results of testing a sample of patients. *Clin Exp Rheumatol* **22**:S5-S13, 2000
34. Bennett RM: Scleroderma overlap syndrome. *Rheum Dis Clin North Am* **16**:185-198, 1990
35. LeRoy EC et al: Undifferentiated connective tissue syndromes. *Arthritis Rheum* **23**:341-343, 1980
36. Poormoghim H et al: Systemic sclerosis sine scleroderma: Demographic, clinical, and serologic features and survival in forty-eight patients. *Arthritis Rheum* **43**:444-451, 2000
37. Rosato E et al: Digital ischemic necrosis in a patient with systemic sclerosis the role of laser Doppler perfusion imaging. *Vasa* **38**:390-393, 2009
38. Clements PJ et al: Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High-dose versus low-dose penicillamine trial. *Arthritis Rheum* **43**:2445-2454, 2000
39. Moore TL et al: Seventeen-point dermal ultrasound scoring system—a reliable measure of skin thickness in patients with systemic sclerosis. *Rheumatology (Oxford)* **42**:1559-1563, 2003
40. Akkesson A et al: Assessment of skin, joint, tendon and muscle involvement. *Clin Exp Rheumatol* **21**:S5-S8, 2003
41. Nives PM et al: Plicometer skin test: A new technique for the evaluation of cutaneous involvement in systemic sclerosis. *Br J Rheumatol* **36**:244-250, 1997
42. Kissin EY et al: Durometry for the assessment of skin disease in systemic sclerosis. *Arthritis Rheum* **55**:603-609, 2006
43. Balbir-Gurmann A et al: Non-invasive measurements of biochemical skin properties in systemic sclerosis. *Ann Rheum Dis* **61**:237-241, 2002
44. Enomoto DN et al: Quantification of cutaneous sclerosis with a skin elasticity meter in patients with generalized scleroderma. *J Am Acad Dermatol* **35**:381-387, 1996
45. Badesch DB et al: Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines. *Chest* **131**:1917-1928, 2007
46. Wells AU et al: Pulmonary complications: One of the most challenging complications of systemic sclerosis. *Rheumatology* **48**:iii40-iii44, 2009
47. Forbes A, Marie I: Gastrointestinal complications: The most frequent internal complications of systemic sclerosis. *Rheumatology* **48**:iii36-iii39, 2008
48. Hunzelmann N et al: Organ-specific diagnosis in patients with systemic sclerosis. Recommendations of the German Network for Systemic Sclerosis (DNSS). *Z Rheumatol* **67**:334-340, 2008
49. Clements PJ et al: Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. *Arthritis Rheum* **36**:75-83, 1993
50. Filaci G et al: Cyclosporin A and iloprost treatment of systemic sclerosis: Clinical results and interleukin-6 serum changes after 12 month of therapy. *Rheumatology (Oxford)* **38**:992-996, 1999
51. Van den Hoogen FH et al: Comparison of methotrexate with placebo in the treatment of systemic sclerosis: A 24 week randomized double-blind trial, followed by a 24 week observational trial. *Br J Rheumatol* **35**:364-372, 1996
52. Pope JE et al: A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. *Arthritis Rheum* **44**:1351-1358, 2001
53. Das SN et al: Placebo controlled trial of methotrexate in systemic sclerosis. *Mymensingh Med J* **14**:7-74, 2005
54. Tashkin DP et al: Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. *N Engl J Med* **354**:2655, 2006
55. Nadashkevich O et al: A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. *Clin Rheumatol* **25**:205-212, 2006

56. Khanna D et al: Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: Results from the scleroderma lung study. *Arthritis Rheum* **56**:1676-1684, 2007
57. van Laar JM et al: Stem cell transplantation: A treatment option for severe systemic sclerosis? *Ann Rheum Dis* **67**:iii35-iii38, 2008
58. Knobler RM et al: A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis. *J Am Acad Dermatol* **54**:793-799, 2006
59. Stratton RJ et al: Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. *Rheumatology (Oxford)* **40**:84-88, 2001
60. Matteson EL et al: Pilot study of antithymocyte globulin in systemic sclerosis. *Arthritis Rheum* **39**:1132-1137, 1996
61. Zamora AC et al: Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. *Respir Med* **102**:150-155, 2008
62. Nihtyanova SI et al: Mycophenolate mofetil in diffuse cutaneous systemic sclerosis—a retrospective analysis. *Rheumatology (Oxford)* **46**:442-445, 2007
63. Su TI et al: Rapamycin versus methotrexate in early diffuse systemic sclerosis: Results from a randomized, single-blind pilot study. *Arthritis Rheum* **60**:3821-3830, 2009
64. Kahan A et al: Nifedipine and alpha 1-adrenergic blockade in Raynaud's phenomenon. *Eur Heart J* **6**:702-705, 1985
65. Meyrick Thomas RH et al: Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis. *Br J Dermatol* **117**:237-241, 1987
66. Rhedda A et al: A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon. *J Rheumatol* **12**:724-727, 1985
67. Challenor VF: Angiotensin converting enzyme inhibitors in Raynaud's phenomenon. *Drugs* **48**:864-867, 1994
68. Dziadzio M et al: Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. *Arthritis Rheum* **42**:2646-2655, 1999
69. Denton CP, Black CM: Novel therapeutic strategies in scleroderma. *Curr Rheumatol Rep* **1**:22-27, 1999
70. Herrick AL et al: A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. *Clin Exp Rheumatol* **18**:349-356, 2000
71. Wigley FM et al: Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study. *Arthritis Rheum* **41**:670-677, 1998
72. Wigley FM et al: Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. *J Rheumatol* **19**:1407-1414, 1992
73. Wise RA et al: Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: A single-center, double-blind, placebo-controlled, randomized crossover study. *Arthritis Rheum* **50**:3994-4001, 2004
74. Denton CP et al: Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study. *Clin Exp Rheumatol* **18**:499-502, 2000
75. Coleiro B et al: Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. *Rheumatology (Oxford)* **40**:1038-1043, 2001
76. Fries R et al: Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. *Circulation* **112**:2980-2985, 2005
77. Kowal-Bielecka O et al: EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). *Ann Rheum Dis* **68**:620-628, 2009
78. Korn JH et al: Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. *Arthritis Rheum* **50**:3985-3993, 2004
79. Krieg T, Takehara K: Skin disease: a cardinal feature of systemic sclerosis. *Rheumatology* **48**:iii14-iii18, 2009
80. Hachulla E, Coghlan JG: A new era in the management of pulmonary arterial hypertension related to scleroderma: Endothelin receptor antagonism. *Ann Rheum Dis* **63**:1009, 2004
81. Steen VD: The lung in systemic sclerosis. *J Clin Rheumatol* **11**:40, 2005
82. Merkel PA et al: Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. *J Rheumatol* **30**:1630, 2003

83. Denton CP, Black CM: Targeted therapy comes of age in scleroderma. *Trends Immunol* **26**:596, 2005
84. Teh LS et al: Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. *Br J Rheumatol* **34**:636-641, 1995